Isomorphic Labs is taking its partnership with Novartis up a notch by tacking on up to three more research initiatives to their collaborative roster.
The brainchild of Google DeepMind’s CEO Demis Hassabis, IsoLabs is leveraging its AI-driven insights to delve deeper into drug discovery alongside the pharmaceutical heavyweight.
Hassabis expressed his enthusiasm, noting the strategic move as “further evidence of the enormous potential impact AI will have on accelerating drug discovery.”
Fiona Marshall from Novartis echoed this sentiment, emphasizing the strides made in the initial collaboration. She stated that the alliance with IsoLabs unlocked new chemical spaces, inaccessible by traditional methods, thereby allowing them to target tricky goals with the potential to address significant unmet needs in healthcare.
This collaboration expands on the initial partnership that was sealed in January 2024.
Founded in 2021, IsoLabs is built on the success of AlphaFold 2, a AI system that accurately predicts protein structures.
IsoLabs has also partnered with Eli Lilly, separately.
In a landscape where developing new drugs can be exorbitantly costly and time-consuming, AI’s role is seen as a game-changer.
Recently, Nvidia CEO Jensen Huang was given the Luminary Award at the Precision Medicine World Conference for the chipmaker’s role in advancing research in life sciences.